LaChapelle Robin 4
4 · ArriVent BioPharma, Inc. · Filed Jul 15, 2025
Insider Transaction Report
Form 4
LaChapelle Robin
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-07-11−6,503→ 6,370 totalExercise: $2.28Exp: 2032-01-31→ Common Stock (6,503 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-07-11−2,600→ 12,873 totalExercise: $2.28Exp: 2032-01-31→ Common Stock (2,600 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-07-11−2,050→ 410 totalExercise: $2.28Exp: 2031-09-07→ Common Stock (2,050 underlying) - Exercise/Conversion
Common Stock
2025-07-11$2.28/sh+2,050$4,674→ 126,633 total - Exercise/Conversion
Common Stock
2025-07-11$2.28/sh+2,600$5,928→ 129,233 total - Exercise/Conversion
Common Stock
2025-07-11$2.28/sh+6,503$14,827→ 135,736 total
Holdings
- 394,477(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.
- [F2]The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F3]The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.